• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Understanding the FDA Imfinzi Combo Approval for Bladder Cancer Care

by MM360 Staff | Apr 25, 2025 | Uncategorized

Source: CureToday articles Dr. Matthew Galsky highlights the impact of Imfinzi’s adjuvant approval for patients with muscle-invasive bladder cancer following cystectomy and chemo. Read More

New Options for ER+ Breast Cancer Spotlighted at Patient Event

by MM360 Staff | Apr 25, 2025 | Uncategorized

Source: CureToday articles Dr. Brian Czerniecki, of Moffitt Cancer Center, led a CURE Educated Patient® Updates in Metastatic Breast Cancer event, and provided subsequent updates. Read More

A Digital Detox for the Soul with Lynch Syndrome

by MM360 Staff | Apr 25, 2025 | Uncategorized

Source: CureToday articles Unplugging from digital noise helped me find peace, clarity and room for growth during a season of emotional and mental renewal. Read More

Decipher Prostate Test Now Available for Metastatic Prostate Cancer

by MM360 Staff | Apr 25, 2025 | Uncategorized

Source: CureToday articles Decipher Prostate Metastatic Genomic Classifier is now available for patients with metastatic prostate cancer. Read More

Evorpacept With Keytruda Did Not Elicit Responses in Head and Neck Cancer

by MM360 Staff | Apr 25, 2025 | Uncategorized

Source: CureToday articles In advanced head and neck squamous cell carcinoma, evorpacept and Keytruda didn’t meet the primary endpoints of the ASPEN-03 and ASPEN trials. Read More

ctDNA Clearance Linked to Improved Survival in Oncogene-Driven NSCLC

by MM360 Staff | Apr 25, 2025 | Uncategorized

Source: CureToday articles Among patients with oncogene-driven advanced NSCLC who were treated with TKIs, ctDNA clearance was associated with improved survival end points. Read More
« Older Entries
Next Entries »

Recent Content

  • (no title)
  • New center promotes advocacy for gynecological cancer patients
  • FDA clears Thermo Fisher EXTENT system for myeloma diagnosis
  • Microbiome modulation uncouples efficacy and toxicity induced by immune checkpoint blockade in mouse multiple myeloma
  • TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial
  • (no title)
  • (no title)
  • New ‘powerful’ lab test will help researchers explore blood cancer
  • Assessing the correlation between patient and family reported outcome measures and multiple myeloma clinical parameters
  • Defining the proteome of bone marrow plasma in multiple myeloma and monoclonal gammopathy of undetermined significance
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT